← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV14행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
Super Hi-TCR-T cells (Super Hi-TCR-T cells)
Eastern Hepatobiliary Surgery Hosp…·Advanced Hepatocellular Carcinoma …
1 trials
Overview
Program
Super Hi-TCR-T cells
Overview
Company
Eastern Hepatobiliary Surgery Hospital
Overview
Modality
CGT
Overview
Target
Advanced Hepatocellular Carcinoma (HCC)
Overview
Indication
Advanced Hepatocellular Carcinoma (HCC)
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Schlafen 11 (SLFN11) overexpression and nucleolar localization in response to bortezomib in multiple myeloma.. Proteins belonging to the Schlafen family are interferon-inducible and participate in the regulation of antiviral responses, immune signaling, and proteotoxic stress. SLFN11 kills cells with replicative damage, serving as a predictive biomarker for chemotherapeutic response. SLFN11 is epi…
Clinical
Safety signal
Schlafen 11 (SLFN11) overexpression and nucleolar localization in response to bortezomib in multiple myeloma.. Proteins belonging to the Schlafen family are interferon-inducible and participate in the regulation of antiviral responses, immune signaling, and proteotoxic stress. SLFN11 kills cells with replicative damage, serving as a predictive biomarker for chemotherapeutic response. SLFN11 is epi…
Clinical
Program phase
PHASE_2